Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study

Annalisa Arcari, Annalisa Chiappella, Michele Spina, Luca Zanlari, Patrizia Bernuzzi, Vanessa Valenti, Monica Tani, Roberto Marasca, Maria Giuseppina Cabras, Renato Zambello, Alberto Santagostino, Fiorella Ilariucci, Giuseppe Carli, Pellegrino Musto, Paolo Savini, Dario Marino, Francesco Ghio, Massimo Gentile, Maria Christina Cox, Daniele Vallisa

Research output: Contribution to journalArticle

Abstract

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not suitable for high dose chemotherapy with autologous stem cell transplantation (ASCT) has a dismal prognosis and no standard therapy. We designed an Italian multicenter retrospective study aimed at evaluating the safety and efficacy of rituximab plus bendamustine (R-B) as salvage treatment in patients not eligible for ASCT because of age and/or comorbidity or in patients with post-ASCT recurrence. Fifty-five patients with a median age of 76 years were included. The overall response rate was 50%, including 28% complete remission and 22% partial remission. The median overall survival (OS) was 10.8 months. The median progression free survival (PFS) was 8.8 months. Eleven patients are still alive and in complete remission at last follow-up (12-71 months). Toxicity was moderate, mainly grades 1 and 2. R-B showed promising efficacy results with an acceptable toxicity profile and should be further investigated, possibly in combination with novel drugs.

Original languageEnglish
Pages (from-to)1823-30
Number of pages8
JournalLeukemia and Lymphoma
Volume57
Issue number8
DOIs
Publication statusPublished - Aug 2016

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Multicenter Studies
Stem Cell Transplantation
Retrospective Studies
Safety
Salvage Therapy
Disease-Free Survival
Comorbidity
Recurrence
Drug Therapy
Survival
Bendamustine Hydrochloride
Rituximab
Pharmaceutical Preparations
Therapeutics

Keywords

  • Journal Article

Cite this

Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients : an Italian retrospective multicenter study. / Arcari, Annalisa; Chiappella, Annalisa; Spina, Michele; Zanlari, Luca; Bernuzzi, Patrizia; Valenti, Vanessa; Tani, Monica; Marasca, Roberto; Cabras, Maria Giuseppina; Zambello, Renato; Santagostino, Alberto; Ilariucci, Fiorella; Carli, Giuseppe; Musto, Pellegrino; Savini, Paolo; Marino, Dario; Ghio, Francesco; Gentile, Massimo; Cox, Maria Christina; Vallisa, Daniele.

In: Leukemia and Lymphoma, Vol. 57, No. 8, 08.2016, p. 1823-30.

Research output: Contribution to journalArticle

Arcari, A, Chiappella, A, Spina, M, Zanlari, L, Bernuzzi, P, Valenti, V, Tani, M, Marasca, R, Cabras, MG, Zambello, R, Santagostino, A, Ilariucci, F, Carli, G, Musto, P, Savini, P, Marino, D, Ghio, F, Gentile, M, Cox, MC & Vallisa, D 2016, 'Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study', Leukemia and Lymphoma, vol. 57, no. 8, pp. 1823-30. https://doi.org/10.3109/10428194.2015.1106536
Arcari, Annalisa ; Chiappella, Annalisa ; Spina, Michele ; Zanlari, Luca ; Bernuzzi, Patrizia ; Valenti, Vanessa ; Tani, Monica ; Marasca, Roberto ; Cabras, Maria Giuseppina ; Zambello, Renato ; Santagostino, Alberto ; Ilariucci, Fiorella ; Carli, Giuseppe ; Musto, Pellegrino ; Savini, Paolo ; Marino, Dario ; Ghio, Francesco ; Gentile, Massimo ; Cox, Maria Christina ; Vallisa, Daniele. / Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients : an Italian retrospective multicenter study. In: Leukemia and Lymphoma. 2016 ; Vol. 57, No. 8. pp. 1823-30.
@article{cb845aee506a40bbb76473c9752b1881,
title = "Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study",
abstract = "Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not suitable for high dose chemotherapy with autologous stem cell transplantation (ASCT) has a dismal prognosis and no standard therapy. We designed an Italian multicenter retrospective study aimed at evaluating the safety and efficacy of rituximab plus bendamustine (R-B) as salvage treatment in patients not eligible for ASCT because of age and/or comorbidity or in patients with post-ASCT recurrence. Fifty-five patients with a median age of 76 years were included. The overall response rate was 50{\%}, including 28{\%} complete remission and 22{\%} partial remission. The median overall survival (OS) was 10.8 months. The median progression free survival (PFS) was 8.8 months. Eleven patients are still alive and in complete remission at last follow-up (12-71 months). Toxicity was moderate, mainly grades 1 and 2. R-B showed promising efficacy results with an acceptable toxicity profile and should be further investigated, possibly in combination with novel drugs.",
keywords = "Journal Article",
author = "Annalisa Arcari and Annalisa Chiappella and Michele Spina and Luca Zanlari and Patrizia Bernuzzi and Vanessa Valenti and Monica Tani and Roberto Marasca and Cabras, {Maria Giuseppina} and Renato Zambello and Alberto Santagostino and Fiorella Ilariucci and Giuseppe Carli and Pellegrino Musto and Paolo Savini and Dario Marino and Francesco Ghio and Massimo Gentile and Cox, {Maria Christina} and Daniele Vallisa",
year = "2016",
month = "8",
doi = "10.3109/10428194.2015.1106536",
language = "English",
volume = "57",
pages = "1823--30",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "8",

}

TY - JOUR

T1 - Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients

T2 - an Italian retrospective multicenter study

AU - Arcari, Annalisa

AU - Chiappella, Annalisa

AU - Spina, Michele

AU - Zanlari, Luca

AU - Bernuzzi, Patrizia

AU - Valenti, Vanessa

AU - Tani, Monica

AU - Marasca, Roberto

AU - Cabras, Maria Giuseppina

AU - Zambello, Renato

AU - Santagostino, Alberto

AU - Ilariucci, Fiorella

AU - Carli, Giuseppe

AU - Musto, Pellegrino

AU - Savini, Paolo

AU - Marino, Dario

AU - Ghio, Francesco

AU - Gentile, Massimo

AU - Cox, Maria Christina

AU - Vallisa, Daniele

PY - 2016/8

Y1 - 2016/8

N2 - Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not suitable for high dose chemotherapy with autologous stem cell transplantation (ASCT) has a dismal prognosis and no standard therapy. We designed an Italian multicenter retrospective study aimed at evaluating the safety and efficacy of rituximab plus bendamustine (R-B) as salvage treatment in patients not eligible for ASCT because of age and/or comorbidity or in patients with post-ASCT recurrence. Fifty-five patients with a median age of 76 years were included. The overall response rate was 50%, including 28% complete remission and 22% partial remission. The median overall survival (OS) was 10.8 months. The median progression free survival (PFS) was 8.8 months. Eleven patients are still alive and in complete remission at last follow-up (12-71 months). Toxicity was moderate, mainly grades 1 and 2. R-B showed promising efficacy results with an acceptable toxicity profile and should be further investigated, possibly in combination with novel drugs.

AB - Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not suitable for high dose chemotherapy with autologous stem cell transplantation (ASCT) has a dismal prognosis and no standard therapy. We designed an Italian multicenter retrospective study aimed at evaluating the safety and efficacy of rituximab plus bendamustine (R-B) as salvage treatment in patients not eligible for ASCT because of age and/or comorbidity or in patients with post-ASCT recurrence. Fifty-five patients with a median age of 76 years were included. The overall response rate was 50%, including 28% complete remission and 22% partial remission. The median overall survival (OS) was 10.8 months. The median progression free survival (PFS) was 8.8 months. Eleven patients are still alive and in complete remission at last follow-up (12-71 months). Toxicity was moderate, mainly grades 1 and 2. R-B showed promising efficacy results with an acceptable toxicity profile and should be further investigated, possibly in combination with novel drugs.

KW - Journal Article

U2 - 10.3109/10428194.2015.1106536

DO - 10.3109/10428194.2015.1106536

M3 - Article

C2 - 26666433

VL - 57

SP - 1823

EP - 1830

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 8

ER -